

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/415, 9/02	A1	(11) International Publication Number: WO 94/27599 (43) International Publication Date: 8 December 1994 (08.12.94)
(21) International Application Number: PCT/EP94/01652 (22) International Filing Date: 24 May 1994 (24.05.94) (30) Priority Data: 9310756.3 25 May 1993 (25.05.93) GB (71) Applicant (for all designated States except US): LABORATOIRES GLAXO S.A. [FR/FR]; 43, rue Vineuse, F-75016 Paris (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): THIELEMANS, Isabelle [FR/FR]; Laboratoires Glaxo S.A., 23, rue Lavoisier, F-27025 Evreux (FR). RICHARD, Isabelle [FR/FR]; Laboratoires Glaxo S.A., 23, rue Lavoisier, F-27025 Evreux (FR). (74) Agents: FILLER, Wendy, Anne et al.; Glaxo Holdings plc, Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, CH, DE, DK, ES, GR, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: RECTAL COMPOSITIONS**(57) Abstract**

The invention relates to a pharmaceutical composition for rectal administration which comprises 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one in the form of its free base or a pharmaceutically acceptable solvate thereof as active ingredient, together with one or more pharmaceutically acceptable carriers or excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine at 5-HT₃ receptors are also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

RECTAL COMPOSITIONS

The present invention relates to a pharmaceutical composition containing, as active ingredient, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one, in particular a composition for rectal administration.

- 5 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one, which may be represented by the formula (I)



10 and its physiologically acceptable salts and solvates are disclosed in GB2153821. The compound of formula (I) is described as a potent and selective antagonist of 5-hydroxytryptamine (5-HT) at "neuronal" 5-HT receptors of the type located on terminals of primary afferent nerves. Receptors of this type are now designated as 5-HT₃ receptors and are also present in the central nervous system. 5-HT occurs widely in the neuronal pathways in the central nervous system and disturbance of these 5-HT containing pathways is known to
15 alter behavioural syndromes such as mood, psychomotor activity, appetite and memory.

20 The compound is described as being of use in the treatment of a human or animal subject suffering from a condition caused by a disturbance of neuronal 5-HT function, for example in the treatment of a human subject suffering from migraine pain or a psychotic disorder such as schizophrenia. It is also stated that the compound may be useful in the treatment of conditions such as anxiety, obesity and mania.

- 2 -

Subsequently published patent applications disclose the use of the compound of formula (I) and other 5-HT₃ antagonists for the treatment of a number of other conditions such as dementia, cognitive disorders and emesis.

- 5 Numerous clinical studies have demonstrated the effectiveness of the compound of formula (I) for the treatment of emesis, particularly the nausea and vomiting associated with cancer chemotherapy and radiotherapy and that occurring post-operatively. Hitherto, the drug has always been administered in the form of a salt, in particular in the form of its hydrochloride dihydrate salt, either by injection or orally.
- 10 Oral administration constitutes the generally preferred route for administration of pharmaceuticals since this route is particularly convenient and acceptable to patients. Unfortunately oral compositions may be associated with certain disadvantages, particularly in the treatment of conditions accompanied by nausea and/or vomiting. It is highly desirable, particularly in the treatment of
- 15 acute conditions, that pharmaceutical compositions have a rapid and consistent onset of action combined with sustained activity and good bioavailability. Rapid absorption can be achieved by parenteral injection but this is unacceptable to some patients, particularly if the drug is to be administered without direct medical supervision i.e. self-administered.
- 20 Alternative routes for administration of the compound of formula (I) are proposed in GB 2153821 including rectal administration. GB 2153821 specifically discloses a number of pharmaceutical formulations containing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one hydrochloride dihydrate as active ingredient and a specific suppository
- 25 formulation for rectal administration containing this active ingredient has been disclosed in, for example, EP-0278161.

The present invention provides a particularly advantageous pharmaceutical formulation, not hitherto specifically disclosed, which is suitable for rectal administration of the compound of formula (I).

- 3 -

There is thus provided according to the invention a pharmaceutical composition for rectal administration which comprises 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one in the form of its free base or a pharmaceutically acceptable solvate thereof as active ingredient, together with one or more pharmaceutically acceptable carriers or excipients.

Unlike the prior art compositions, the compositions according to the invention contain the active ingredient in the form of its free base or a pharmaceutically acceptable solvate thereof. The applicants have found that the use of the free base rather than the hydrochloride salt of the compound of formula (I) is surprisingly advantageous when the active ingredient is administered rectally.

The compositions according to the invention may be in the form of retention enemas, solid dosage forms such as suppositories or soft gelatin capsules, or semi solid dosage forms such as a rectal gel or cream. Preferably the compositions are formulated as solid unit dosage forms suitably shaped, for example conical, cylindrical or torpedo-shaped, for rectal administration. The solid dosage forms may either melt at body temperature or dissolve or disperse in the mucous secretions of the cavity.

Conventional carriers which may be employed in the compositions according to the invention include theobroma oil, hard fats, glycerides of fatty acids, glycerol-gelatin bases, macrogols (polyethylene glycols) and mixtures thereof. Preferred compositions comprise hard fat bases such as esterified, hydrogenated or fractionated vegetable oils and synthetic triglyceride mixtures produced under the name of adeps solidus.

Preferred hard fat bases are hard fats containing a mixture of mono-, di- and triglycerides of saturated C₉-18 fatty acids. Preferably the hard fat base comprises hard fats obtained by esterification of fatty acids of vegetable origin with glycerol, a macrogol ther containing 20 to 24 oxyethylene groups in the polyoxyethylene chain .g. polyoxyl-20-cetostearyl ether, and glycerides .g. glyceryl ricinoleate. Preferably the hard fat base has a high Hydroxyl Value

- 4 -

(USP Chemical Test), for example a Hydroxyl Value of between 20 and 100, such as 40 to 80, in particular 60 to 70.

5 Solid dosage forms such as suppositories may be prepared in conventional manner for example by intimate admixture of the active ingredient with the carrier, preferably the molten carrier. Preferably the active ingredient is milled or sieved prior to incorporation into the molten carrier. The molten composition may then be poured into suitable moulds, for example PVC, polyethylene or aluminium moulds. Optionally the suppositories may be coated, prior to
10 packing, for example with cetyl alcohol, macrogol or polyvinyl alcohol and polysorbates to increase disintegration time or lubrication or to reduce adhesion on storage.

Preferably the total weight of the solid dosage form is about 1 or 2 grams and the active ingredient may comprise 0.05 to 20% by weight of the composition, preferably 0.1 to 20% by weight of the composition, more preferably 0.2 to 5%
15 by weight of the composition, such as 0.4 to 3.2%.

The amount of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one free base employed in the compositions of the invention will preferably be in the range of about 0.1mg to about 100mg, more preferably about 1mg to about 50mg, such as about 2mg to about 35mg, for
20 example about 5mg to about 20mg.

A further aspect of the invention provides a method of treating a mammal, including man, suffering from or susceptible to a condition mediated through the action of 5-hydroxytryptamine at 5-HT₃ receptors which comprises rectal administration of a pharmaceutical composition which comprises 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one in
25 the form of its free base or a pharmaceutically acceptable solvate thereof as active ingredient, together with one or more pharmaceutically acceptable carriers or excipients. It will be appreciated that reference to treatment is

- 5 -

intended to include prophylaxis as well as the alleviation of established symptoms.

5 Conditions mediated through the action of 5-HT at 5-HT₃ receptors include cognitive disorders such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease and Creutzfeldt-Jakob disease), and vascular
10 dementia (including multi-infarct dementia), as well as dementia associated with intracranial space occupying lesions, trauma, infections and related conditions (including HIV infection), metabolism, toxins, anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment; psychotic disorders, such as schizophrenia and mania; anxiety disorders, including panic disorder, agoraphobia, social phobia, simple phobia, obsessive compulsive disorders, post traumatic stress disorder, mixed anxiety and depression, and generalised anxiety disorder; nausea and vomiting,
15 particularly that associated with cancer chemotherapy and radiotherapy and also that occurring post operatively; irritable bowel syndrome and dependency on drugs and substances of abuse. Other conditions mediated in this manner include gastric stasis; symptoms of gastrointestinal dysfunction such as occur with peptic ulcer, reflux oesophagitis, flatulence and dyspepsia; migraine;
20 obesity and conditions such as bulimia; pain; and depression.

The pharmaceutical compositions according to the invention have particular utility for the treatment of nausea and vomiting, particularly that associated with cancer chemotherapy and radiotherapy, but also that occurring post-operatively.

25 It will be appreciated that the precise therapeutic dose of the active ingredient will depend on the age and condition of the patient and the nature of the condition to be treated and will be at the ultimate discretion of the attendant physician.

However, in general, effective doses for the treatment of conditions mediated through the action of 5-hydroxytryptamine at 5-HT₃ receptors, for example post-

- 6 -

operative nausea and vomiting will lie in the range of 0.1 to 200mg, preferably 0.5 to 100mg, most preferably 1 to 50mg, for example 4, 8, 16 or 32mg of the active ingredient per unit dose which could be administered in single or divided doses, for example, 1 to 4 times per day.

- 5 The invention is further illustrated by the following non-limiting examples.

Example 1

Suppository for Rectal Administration

Unit Formula
(per suppository)

1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one
(sieved free base)

8mg

Mixture of hard fats NF17, polyoxy-20-cetostearyl-ether NF17 and glyceryl ricinoleate (sold under the trade name Witepsol S58)
Hydroxyl Value 60 to 70

to 1g

A suspension of the active ingredient in molten base was prepared and filled in conventional manner into 1g size suppository moulds.

- 10 Examples 2, 3, 4 and 5

Suppositories containing 1, 2, 4 or 16mg 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one (sieved free base) were prepared as described for the suppositories of Example 1.

- 7 -

Example 6Suppository for Rectal AdministrationUnit Formula
(per suppository)1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one
(sieved free base)

16mg

Mixture of hard fats NF17, polyoxy-20-cetostearyl-ether NF17 and glyceryl ricinoleate (sold under the trade name Witepsol S58)
Hydroxyl Value 60 to 70

to 2g

A suspension of the active ingredient in molten base was prepared and filled in conventional manner into 2g size suppository moulds.

Examples 7 and 8

- 5 Suppositories containing 8 or 32mg 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one (sieved free base) were prepared as described for the suppositories of Example 6.

Example 9

- 10 Suppositories containing 4mg 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one (sieved free base) are prepared as described for the suppositories of Example 6.

- 8 -

Claims

1. A pharmaceutical composition for rectal administration which comprises 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one in the form of its free base or a pharmaceutically acceptable solvate thereof as active ingredient, together with one or more pharmaceutically acceptable carriers or excipients.
2. A pharmaceutical composition as claimed in claim 1 in a solid dosage form.
3. A pharmaceutical composition as claimed in claim 1 or 2 in the form of a suppository.
4. A pharmaceutical composition as claimed in any one of claims 1 to 3 wherein the pharmaceutical carrier comprises hard fat bases.
5. A pharmaceutical composition as claimed in claim 4 wherein the hard fat base has a Hydroxyl Value of between 20 to 100.
6. A pharmaceutical composition as claimed in any of claims 1 to 5 which comprises 0.05 to 20% by weight of active ingredient.
7. A pharmaceutical composition as claimed in any one of claims 1 to 6 which comprises 0.1 to 100mg of active ingredient.
8. A method of manufacture of a pharmaceutical composition as claimed in any one of claims 1 to 7 which comprises intimate admixture of the active ingredient with the carrier.
9. A method of treating a mammal, including man, suffering from or susceptible to a condition mediated through the action of 5-hydroxytryptamine at

- 9 -

5 5-HT₃ receptors which comprises rectal administration of a pharmaceutical composition which comprises 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one in the form of its free base or a pharmaceutically acceptable solvate thereof as active ingredient, together with one or more pharmaceutically acceptable carriers or excipients.

10. A method according to claim 9 wherein the condition is nausea and vomiting.

INTERNATIONAL SEARCH REPORT

 Int'l Application No
 PCT/EP 94/01652

 A. CLASSIFICATION F SUBJECT MATTER
 IPC 5 A61K31/415 A61K9/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR,A,2 633 831 (GLAXO GROUP LTD) 12 January 1990 see page 2, line 25 - line 30 see page 3, line 2 - line 9 see page 4, line 2 - line 6 see page 6, line 17 - line 20 see page 8, line 8 - line 17 see claims 1,9 ---	1-3,9,10
X	WO,A,92 04012 (ALZA CORPORATION) 19 March 1993 see page 15 - page 17; example 1 --- -/--	1,2

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

9 September 1994

Date of mailing of the international search report

20.09.94

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/EP 94/01652

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 278 161 (GLAXO GROUP LTD) 17 August 1988 cited in the application see page 3, line 45 - line 46 see page 4; example 2 see page 11, line 41 - line 48 ---	1-10
A	BOYLAN J.C. ET AL 'Handbook of Pharmaceutical Excipients' 1986 , AMERICAN PHARMACEUTICAL ASSOCIATION & THE PHARMACEUTICAL SOCIETY OF GREAT BRITAIN , WASHINGTON LONDON see page 314 - page 320 -----	1-8

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 94/01652

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2633831	12-01-90	AU-B- 633496	04-02-93
		AU-A- 3790489	11-01-90
		BE-A- 1002295	20-11-90
		CA-A- 1330306	21-06-94
		CH-A- 679553	13-03-92
		DE-A- 3922263	11-01-90
		GB-A, B 2220352	10-01-90
		JP-A- 2076815	16-03-90
		NL-A- 8901727	01-02-90
		SE-A- 8902458	08-01-90
		US-A- 4983621	08-01-91
WO-A-9204012	19-03-92	US-A- 5166145	24-11-92
		AU-A- 8536691	30-03-92
		US-A- 5310561	10-05-94
		US-A- 5246709	21-09-93
EP-A-0278161	17-08-88	AU-B- 608788	18-04-91
		AU-A- 8144387	26-05-88
		DE-A- 3777805	30-04-92
		DE-A- 3778008	07-05-92
		EP-A, B 0279114	24-08-88
		WO-A- 8803801	02-06-88
		JP-A- 63185927	01-08-88
		JP-T- 1502186	03-08-89
		US-A- 5298510	29-03-94
		US-A- 4847281	11-07-89
		US-A- 4948803	14-08-90
		US-A- 5198447	30-03-93